AU2022425559A1 - Compositions and methods for treating huntington's disease - Google Patents
Compositions and methods for treating huntington's disease Download PDFInfo
- Publication number
- AU2022425559A1 AU2022425559A1 AU2022425559A AU2022425559A AU2022425559A1 AU 2022425559 A1 AU2022425559 A1 AU 2022425559A1 AU 2022425559 A AU2022425559 A AU 2022425559A AU 2022425559 A AU2022425559 A AU 2022425559A AU 2022425559 A1 AU2022425559 A1 AU 2022425559A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- clq
- level
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295213P | 2021-12-30 | 2021-12-30 | |
| US63/295,213 | 2021-12-30 | ||
| US202263349305P | 2022-06-06 | 2022-06-06 | |
| US63/349,305 | 2022-06-06 | ||
| PCT/US2022/082523 WO2023130001A1 (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022425559A1 true AU2022425559A1 (en) | 2024-07-04 |
Family
ID=87000332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022425559A Pending AU2022425559A1 (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4457244A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126863A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022425559A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313901A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023130001A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) * | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2022
- 2022-12-29 US US18/725,580 patent/US20250074973A1/en active Pending
- 2022-12-29 JP JP2024539560A patent/JP2025503545A/ja active Pending
- 2022-12-29 AU AU2022425559A patent/AU2022425559A1/en active Pending
- 2022-12-29 EP EP22917557.5A patent/EP4457244A4/en active Pending
- 2022-12-29 IL IL313901A patent/IL313901A/en unknown
- 2022-12-29 KR KR1020247023399A patent/KR20240126863A/ko active Pending
- 2022-12-29 MX MX2024008273A patent/MX2024008273A/es unknown
- 2022-12-29 WO PCT/US2022/082523 patent/WO2023130001A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4457244A4 (en) | 2026-01-07 |
| EP4457244A1 (en) | 2024-11-06 |
| US20250074973A1 (en) | 2025-03-06 |
| JP2025503545A (ja) | 2025-02-04 |
| IL313901A (en) | 2024-08-01 |
| MX2024008273A (es) | 2024-07-19 |
| KR20240126863A (ko) | 2024-08-21 |
| WO2023130001A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7275223B2 (ja) | ヒト化抗補体因子C1q抗体及びその使用 | |
| JP7106386B2 (ja) | コロニー刺激因子1受容体(csf1r)を結合する抗体によって状態を治療する方法 | |
| JP6646100B2 (ja) | 抗cxcr3抗体 | |
| US20180303936A1 (en) | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists | |
| TWI564305B (zh) | 治療性抗體 | |
| JP7617848B2 (ja) | ピログルタメートアミロイド-βに対する抗体及びその使用 | |
| US20170290913A1 (en) | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists | |
| ES2738305T3 (es) | Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales | |
| JP2021514969A (ja) | 抗tigit及び抗pd−l1アンタゴニスト抗体による治療のための投薬 | |
| AU2019370485B2 (en) | Compositions and methods for treating brain injury | |
| IL296130A (en) | Anti-complement factor c1q fab fragments and their uses | |
| IL293386A (en) | Methods of use of anti-trem2 antibodies | |
| US20250230225A1 (en) | Compositions and methods for treating muscular dystrophy | |
| KR20230024368A (ko) | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 | |
| US20240034775A1 (en) | Compositions and methods for treating epilepsy | |
| WO2022046614A1 (en) | Methods for reducing maternal autoantibodies | |
| EP4228696A1 (en) | Compositions and methods for treating blood disorders | |
| US20250074973A1 (en) | Compositions and methods for treating huntington’s disease | |
| US20250313615A1 (en) | Compositions and methods for treating lupus nephritis | |
| CN118525031A (zh) | 用于治疗亨廷顿氏病的组合物和方法 | |
| HK40114489A (zh) | 用於治疗亨廷顿氏病的组合物和方法 | |
| TW201400501A (zh) | 新穎抗體及其用途 |